


BARD (C.R.), INC. NYSE-BCR

RECENT PRICE **83.04** P/E RATIO **15.1** (Trailing: 16.1 Median: 20.0) RELATIVE P/E RATIO **0.92** DIV'D YLD **0.8%** **VALUE LINE**

TIMELINESS 3 Lowered 6/26/09
SAFETY 1 Raised 12/1/06
TECHNICAL 2 Raised 4/30/10
BETA .60 (1.00 = Market)



2013-15 PROJECTIONS

	Price	Gain	Ann'l Total Return
High	155	(+85%)	17%
Low	125	(+50%)	11%

Insider Decisions

	J	A	S	O	N	D	J	F	M
to Buy	0	0	0	0	0	0	0	0	0
Options	1	1	1	1	1	1	1	3	1
to Sell	1	4	2	2	3	1	1	7	2

Institutional Decisions

	2Q2009	3Q2009	4Q2009
to Buy	229	213	251
to Sell	252	225	208
Hlds(000)	86717	84297	82190

1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	© VALUE LINE PUB., INC.	13-15
9.78	9.96	10.48	10.69	11.31	10.21	10.79	11.28	12.34	13.85	15.82	17.03	19.25	21.98	24.67	26.43	28.70	30.90	Sales per sh	42.80
1.26	1.32	1.41	1.35	1.50	1.64	1.72	1.87	2.12	2.40	3.03	3.76	4.14	4.85	5.50	6.29	6.60	7.30	"Cash Flow" per sh	9.05
.89	.89	.91	.83	.86	1.14	1.23	1.38	1.68	1.94	2.45	3.03	3.29	3.84	4.44	4.79	5.50	6.20	Earnings per sh ^A	7.80
.29	.31	.33	.35	.37	.39	.41	.42	.43	.45	.47	.50	.54	.58	.62	.66	.70	.74	Div'ds Decl'd per sh ^B	.85
.33	.35	.37	.29	.43	.26	.19	.26	.40	.70	.71	.93	.68	.51	.51	.50	.60	.75	Cap'l Spending per sh	.95
4.23	4.94	5.28	5.05	5.51	5.65	6.03	7.53	8.53	10.10	12.99	14.77	16.46	18.44	19.89	22.87	20.40	22.85	Book Value per sh ^C	39.25
104.10	114.20	113.97	113.57	103.00	101.56	101.82	104.77	103.21	103.51	104.67	104.01	103.16	100.19	99.39	95.92	95.00	92.50	Common Shs Outst'g ^D	90.00
14.5	16.3	17.6	19.0	22.2	22.2	18.4	18.9	16.4	17.6	21.9	22.0	22.3	21.7	20.5	15.3	18.0	18.0	Avg Ann'l P/E Ratio	18.0
.95	1.09	1.10	1.10	1.15	1.27	1.20	.97	1.00	1.16	1.17	1.20	1.15	1.23	1.02	1.02	1.23	1.02	Relative P/E Ratio	1.20
2.3%	2.1%	2.1%	2.2%	1.9%	1.5%	1.8%	1.6%	1.6%	1.3%	.9%	.7%	.7%	.7%	.8%	.8%	1.2%	1.2%	Avg Ann'l Div'd Yield	.6%

CAPITAL STRUCTURE as of 3/31/10
 Total Debt \$149.8 mill. Due in 5 Yrs \$50.0 mill.
 LT Debt \$149.8 mill. LT Interest \$10.0 mill.
 (% of Cap'l)

Leases, Uncapitalized Annual Rentals \$22.4 mill.

Pension Assets-12/09 \$239.1 mill. **Oblig.** \$348.6 mill.

Pfd Stock None

Common Stock 95,097,102 shares
MARKET CAP: \$7.9 billion (Large Cap)

	2008	2009	3/31/10		2008	2009	3/31/10	
Cash Assets	592.1	674.4	733.8	BUSINESS: C.R. Bard, Inc. has four core segments: Vascular	1098.8	1181.3	1273.8	1433.1
Receivables	394.1	442.1	430.8	(27% of '09 sales): angioplasty & angiography catheters, stents,	22.2%	22.6%	23.1%	23.2%
Inventory (LIFO)	275.1	295.4	279.1	vasc. grafts & blood oxygenators. Urology (27%): <i>Foley</i> catheters,	49.6	53.2	42.3	44.7
Other	92.9	79.9	81.9	urine collection sys. & incontinence aids. Oncology (27%): speciality	125.3	143.2	176.9	204.0
Current Assets	1354.2	1491.8	1525.6	access catheters & ports, gastroenterological pdts. & bladder	30.2%	30.1%	28.1%	27.5%
Accts Payable	53.5	50.8	54.9	& prostate cancer tests. Surgical Specialties (15%): hernia repair	11.4%	12.1%	13.9%	14.2%
Debt Due	--	--	--		302.1	412.9	441.1	453.2
Other	219.6	230.9	209.3		204.3	156.4	152.2	151.5
Current Liab.	273.1	281.7	264.2		613.9	788.7	880.4	1045.7
					16.5%	15.9%	17.7%	17.6%
					20.4%	18.2%	20.1%	19.5%
					13.6%	12.7%	15.0%	15.0%
					33%	30%	25%	23%

CURRENT POSITION

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2007	528.2	545.7	544.8	583.3	2202.0
2008	584.0	617.1	616.8	634.2	2452.1
2009	596.4	624.6	637.0	676.9	2534.9
2010	650.8	670	680	724.2	2725
2011	675	710	725	750	2860

EARNINGS PER SHARE ^A

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2007	.95	.91	.96	1.02	3.84
2008	1.06	1.10	1.10	1.19	4.44
2009	1.17	1.23	1.31	1.08	4.79
2010	1.24	1.36	1.45	1.45	5.50
2011	1.40	1.50	1.60	1.70	6.20

QUARTERLY DIVIDENDS PAID ^B

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2006	.13	.13	.14	.14	.54
2007	.14	.14	.15	.15	.58
2008	.15	.15	.16	.16	.62
2009	.16	.16	.17	.17	.68
2010	.17	.17			

C.R. Bard is building momentum. The medical equipment company got off to a strong start in 2010. First-quarter revenues advanced 9% and share net grew 6%, year over year. Improved market conditions helped bolster results domestically, and international sales were up roughly 15% during the interim. In addition, we believe that Bard's well-diversified portfolio mix strengthened the quarterly performance. Looking forward, **The company ought to post solid top and bottom-line near-term results.** Its business development efforts and ongoing initiatives should help offset the pressures of a somewhat more competitive environment. Management has been focusing on technological improvements. As a result, it has increased research and development spending. Product innovation should be key to long-term gains. In the first quarter, eight product launches were well received. Also, BCR's ongoing stock-repurchase program should help boost per-share comparisons. In sum, we look for revenues to grow another 5%-10% this year. Moreover, profits should continue to grow at a 10%-15% annual clip in 2010

and 2011. **Acquisitions ought to help, too.** In the beginning of the second quarter, Bard purchased FlowCardia for \$80 million. This addition should advance its lower-limb arterial business strategy. And in early May, Bard announced plans to acquire SenoRx, Inc. for \$11.00 a share, for net proceeds of \$200 million. SenoRx makes devices that help detect and treat breast cancer. The transaction, which is still subject to regulatory approval, ought to complement the Peripheral Vascular division. The company will probably eye additional asset purchases that will be accretive to its product pipeline. **This issue has some room to run.** As the baby-boomer generation ages, and relies more heavily on healthcare services, it will lift demand for Bard's products. Even though BCR is now ranked to only track the broader market averages, it offers worthwhile capital gains possibilities over the next 3 to 5 years. What's more, the company's sterling finances and perfect scores for Price Stability and Safety may appeal to conservative investors.

Orly Seidman
 May 28, 2010

(A) Based on avg. shs. outstanding until '96, dil. thereafter. Excl. net n/r.: '94, d17c; '95, d12c; '96, d10c; '97, d20c; '98, \$1.40; '99, 1c; '00, d18c; '02, d21c; '03, d34c; '04, 37c; '05, 9c; '06, d74c; '08, d38c; '09, Q1, d7c; Q2, d12c. Incl. one-time gain from add'l month of acctg. for fgn. operations: '98, 2c. Qtrly eggs. may not sum due to rounding. Next eggs. rpt. due late April. (B) Dividends hist. paid in early Feb., May, Aug., and Nov. ■ Div'd reinv. plan avail. (C) Incl. intang. In '09: \$913.8 mill., \$9.53/sh. (D) In mill., adj. for split.

Company's Financial Strength	A++
Stock's Price Stability	100
Price Growth Persistence	100
Earnings Predictability	100

To subscribe call 1-800-833-0046.